详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China. [3]Institute for Breast Health Medicine, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, 610041, China.

出处：

DOI：

关键词： ER+/HER2- early breast cancer Estrogen receptor Progesterone receptor Difference Prognostic

摘要：

ER+/HER2- breast cancer is a common subtype of breast cancer. This study aimed to evaluate the prognostic value of ER-to-PR difference (EPD) in ER+/HER2- early breast cancer (EBC). A retrospective cohort study was conducted, including 3,340 ER+/HER2- EBC patients, divided into a training cohort of 2,873 patients and a validation cohort of 467 patients. The optimal EPD cutoff value for stratifying patients was determined using X-tile. Additionally, the prognostic value of EPD, when combined with other clinicopathological factors, was assessed using the Cox proportional hazards model and five traditional machine learning methods. The optimal cutoff value for EPD was determined as 10%, categorizing patients into EPD-low (ER-PR ≤ 10%) and EPD-high (ER-PR > 10%) expression groups. Patients with EPD-high tumors exhibited a poorer prognosis compared to those with EPD-low tumors. In the multivariate Cox model, EPD was identified as an independent prognostic factor for disease-free survival (DFS) (HR: 1.496, P = 0.004). Integrating EPD with clinicopathological parameters into a predictive model effectively predicts DFS in ER+/HER2- EBC patients. In the most effective CoxPH model, the area under the curve (AUC) values for predicting 3-year, 5-year, and 7-year DFS were 0.718, 0.702, and 0.701, respectively, in the WCH cohort, and 0.770, 0.739, and 0.743, respectively, in the FUSCC cohort. EPD may serve as a novel prognostic marker, allowing for the identification of a population with a poor prognosis in ER+/HER2- EBC, thereby aiding clinical decision-making.© 2024. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区综合性期刊

小类 | 2 区综合性期刊

第一作者：

第一作者机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The Novel Role of Cytomorphology from Ultrasound-Guided Fine Needle Aspiration Cytology in Evaluating the Status of Prognostic Factors including Estrogen Receptor, Progesterone Receptor and HER2 in Breast Cancer. [2]Prognostic value of progesterone receptor status in Chinese breast cancer patients treated with tamoxifen [3]Estrogen, Estrogen Receptor and Lung Cancer [4]Prognostic value of progesterone receptor status in Chinese breast cancer patients treated with tamoxifen [5]G protein-coupled receptor 30 in tumor development [6]The clinical impact of plasma estrogen receptor-1 mutation in patients with metastatic breast cancer: A meta-analysis [7]原发性肝癌雌激素受体表达及内分泌治疗 [8]乳腺增生症与ESR1基因遗传多态性的相关性研究 [9]Involvement of estrogen receptor β in androgen receptor-induced growth inhibition in prostate cancer PC-3 cells. [10]Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.